vancomycin has been researched along with Skin Diseases, Bacterial in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.16) | 18.2507 |
| 2000's | 22 (23.16) | 29.6817 |
| 2010's | 66 (69.47) | 24.3611 |
| 2020's | 4 (4.21) | 2.80 |
| Authors | Studies |
|---|---|
| Amsler, K; Heep, M; Noel, GJ; Pypstra, R; Solomkin, JS; Strauss, RS | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Abutaleb, NS; Dayal, N; Mohammad, H; Naclerio, GA; Opoku-Temeng, C; Seleem, MN; Sintim, HO | 1 |
| Acquisto, NM; Cheon, E; Sacdal, JPA; Stilwell, AM; Treu, CN | 1 |
| Claeys, KC; Davis, SL; Delaportes, DJ; Estrada, SJ; Huang, V; Jorgensen, SCJ; Kaye, KS; Klinker, KP; Lagnf, AM; Rybak, MJ; Trinh, TD; Zasowski, EJ | 1 |
| Engelhardt, M; Gonzalez-Rojas, Y; Gumenchuk, I; Hamed, KA; Ionescu, D; Jones, ME; Keech, R; Kim, C; Ninov, B; Overcash, JS; Saulay, M; Simeonov, S; Smart, JI; Waters, M | 1 |
| Galindo, M; Ikuta, I; Jordán, J; Monteagudo-Martínez, N; Nava, E; Solís-García Del Pozo, J | 1 |
| González-Barreto, RM; Martín, RF; Rochet, NM | 1 |
| Cammarata, S; Farley, B; Gardovskis, J; Lawrence, L; Ling, R; Pullman, J; Quintas, M; Sun, E | 1 |
| Bianchi, L; D'Adamio, S; Galluzzo, M; Talamonti, M | 1 |
| Amin, F; Corey, GR; Dryden, M; File, TM; Heller, B; Holland, TL; Huang, DB; McLeroth, P; O'Riordan, W; Overcash, JS; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Cammarata, S; Cruz-Saldariagga, M; Lawrence, L; Liang, S; McManus, A; O'Riordan, W; Poromanski, I; Quintas, M; Teras, J | 1 |
| Borghei, A; Corey, GR; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; McLeroth, P; McManus, A; O'Riordan, W; Oguri, T; Shin, E; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH | 1 |
| Butler-Laporte, G; Cheng, MP; De L'Étoile-Morel, S; Lee, TC; McDonald, EG | 1 |
| Chastain, DB; Davis, A | 1 |
| Balser, B; Corey, GR; Huang, DB; Noviello, S; Scaramucci, A | 1 |
| Chen, XJ; Gao, W; Hua, CZ; Jing, CM; Lin, AW; Lu, HP; Lyu, Q; Wang, CQ; Xu, HM; Xu, ZW; Yang, LH; Yu, H | 1 |
| Ivezic-Schoenfeld, Z; Lell, C; Novak, R; Obermayr, F; Prince, WT; Tack, KJ; Talbot, GH | 1 |
| Adamson, RT; Amara, S; Huang, X; Lew, I | 1 |
| Beresford, E; Friedland, HD; Huang, X; Lodise, T | 1 |
| Chen, X; Dong, BR; Liu, GJ; Wu, T; Yang, M; Yue, J | 2 |
| Hanna, N; Yazdani, C | 1 |
| Gould, IM; O'Brien, DJ | 1 |
| Dhanireddy, R; Dolapo, O; Talati, AJ | 1 |
| Boucher, HW; Das, AF; Dunne, MW; Puttagunta, S; Talbot, GH; Wilcox, M | 1 |
| Corey, GR; Giordano, P; Good, S; Gupta, S; Jiang, H; Kabler, H; Lucasti, C; Mehra, P; Moeck, G; O'Riordan, W; Overcash, JS; Perez, A; Porwal, A | 1 |
| Chambers, HF | 1 |
| Fan, W; Kongnakorn, T; LaPensee, KT; Pelligra, CG; Revankar, N; Ward, AJ | 1 |
| Holmes, NE; Howden, BP | 1 |
| Boucher, HW; Dunne, MW; Talbot, GH | 1 |
| Núñez-Núñez, M; Rodríguez-Baño, J | 1 |
| Baang, J; Fisher, S | 1 |
| Cormican, M | 1 |
| Corey, GR; Jiang, H; Moeck, G | 1 |
| Bubnova, N; Corey, GR; Good, S; Green, S; Heller, B; Jiang, H; Keech, R; Manos, P; Moeck, G; O'Riordan, W; Singh, R; Wikler, M | 1 |
| Mylonakis, E; Zacharioudakis, IM; Zervou, FN | 1 |
| Steiner, M | 1 |
| Eckmann, C | 1 |
| Boucher, HW; Corey, GR; Stryjewski, ME | 1 |
| DiNubile, MJ | 1 |
| Fuller, BM; McCammon, C; Mueller, K; Skrupky, L | 1 |
| Nathwani, D; Tsoulas, C | 1 |
| Corey, GR; Halfpenny, N; Scott, DA; Sulham, K; Thom, H; Thompson, JC | 1 |
| Bland, CM; Bookstaver, PB | 1 |
| English, TM; McCreary, EK; Wargo, KA | 1 |
| Arhin, FF; Biedenbach, DJ; Lynch, TF; Moeck, G; Sahm, DF | 1 |
| Cammarata, SK; Duffy, E; Henry, E; Kingsley, J; Lawrence, LE; Mehra, P; Pullman, J | 1 |
| Mehta, SA; Russo, HR | 1 |
| Fan, W; Lodise, TP; Sulham, KA | 1 |
| Dryden, M; Gonzalez, J; Iaconis, JP; Wilson, D; Zhang, Y | 1 |
| Chemaly, RF; Nesher, L; Rolston, KV; Tarrand, J | 1 |
| Arber, M; Barata, T; Eales, J; Fleetwood, K; Glanville, J; Gould, IM; Kauf, TL; McCool, R | 1 |
| Anastasiou, D; Arnold, SR; Arrieta, A; Bokesch, P; Bradley, J; Congeni, B; Daum, RS; Glasser, C; Kojaoghlanian, T; Patino, H; Wolf, DJ; Yoon, M | 1 |
| Buckwalter, M; Damle, B; Dowell, JA; Goldstein, BP; Stogniew, M | 1 |
| Croos-Dabrera, RV; Ijzerman, MM; Lin, DF; Miao, JZ; Shen, HH; Sheng, RY; Sheng, W; Wang, F; Wu, JF; Zhang, YY; Zheng, JC; Zheng, LY; Zhou, X | 1 |
| Stein, RA | 1 |
| Cooper, A; Dartois, N; Dukart, G; Gardovskis, J; Jouve, S; Kupcs, U; Pupelis, G; Teras, J; Vaasna, T | 1 |
| Bouza, E; Croos-Dabrera, RV; Herr, DL; Ijzerman, MM; Knirsch, C; Kunkel, MJ; Ruf, BR; Tack, KJ; Wilcox, MH | 1 |
| Akhras, KS; Budd, D; Itani, KM; Merchant, S; Quintana, A; Stellhorn, R | 1 |
| Beibei, L; Mengli, C; Nan, B; Rui, W; Xuhong, Y; Yun, C | 1 |
| Stein, GE; Wells, EM | 1 |
| Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW | 1 |
| Barriere, SL; Benton, BM; Kitt, MM; Krause, KM | 1 |
| Barriere, SL | 1 |
| Ang, JY; Deville, JG; Equils, O; Huang, DB | 1 |
| Baculik, T; Corey, GR; Friedland, D; Talbot, GH; Thye, D; Wilcox, MH | 2 |
| Corrado, ML | 1 |
| Jones, RN; Mendes, RE; Pfaller, MA; Rhomberg, PR; Sader, HS | 1 |
| Bai, N; Cai, Y; Liang, B; Liu, Y; Wang, R | 1 |
| Aradhya, S; Chang, CM; Chuang, YC; Cooper, A; Dartois, N; Jouve, S; Nagari, B; Pai, V | 1 |
| Dowzicky, MJ; Namdari, H; Tan, TY | 1 |
| Biedenbach, DJ; Ivezic-Schoenfeld, Z; Jones, RN; Paukner, S; Sader, HS | 1 |
| Drusano, GL | 1 |
| Biek, D; Eckburg, PB; Friedland, HD; Laudano, JB; Llorens, L; O'Neal, T; Rank, DR; Smith, A; Thye, D; Witherell, GW | 1 |
| Barriere, SL; Churukian, A; Corey, GR; Kingsley, J; Li, YP; Potgieter, PD; Stryjewski, ME | 1 |
| Boulinguez, S; Viraben, R | 1 |
| Li, JZ; Rittenhouse, BE; Rybak, MJ; Willke, RJ | 1 |
| Adler, S; Bruss, JB; Edge-Padbury, B; Kaplan, SL; Martin, A; Morfin, MR; Naberhuis-Stehouwer, S; Patterson, LE; Yogev, R | 1 |
| Dissemond, J; Esser, S; Goos, M; Schmid, EN; Witthoff, M | 1 |
| Barriere, SL; Cabell, CH; Chu, VH; Corey, GR; Dunbar, LM; Fowler, VG; Kitt, MM; Lau, WK; O'Riordan, WD; Pien, FD; Spencer, E; Stryjewski, ME; Vallee, M | 1 |
| Dryden, M; Itani, K; Knirsch, C; Lau, W; Stevens, D; Weigelt, J | 1 |
| Babinchak, T; Dartois, N; Ellis-Grosse, EJ; Loh, E; Rose, G | 1 |
| Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S | 1 |
| Wilcox, MH | 1 |
| Breedt, J; Dartois, N; Ellis-Grosse, EJ; Gardovskis, J; Gioud-Paquet, M; Loh, E; Maritz, FJ; Ross, DP; Teras, J; Vaasna, T | 1 |
| Charles, PG; Grayson, ML; Howden, BP; Johnson, PD; Ward, PB | 1 |
| Barriere, SL; Chu, VH; Corey, GR; Dunbar, LM; Fowler, VG; Kitt, MM; Morganroth, J; O'Riordan, WD; Stryjewski, ME; Vallée, M; Warren, BL; Young, DM | 1 |
| Scheinfeld, N | 1 |
| Bagchi, P; Bush, K; Ianus, J; Noel, GJ; Strauss, RS | 1 |
| De Pauw, BE; Deresinski, SC; Dompeling, EC; Donnelly, JP; Feld, R; Lane-Allman, EF | 1 |
| Akiyama, H; Arata, J; Kanzaki, H; Tada, J; Yamasaki, O | 1 |
| Barriere, SL; Dunn, DL; Graham, DR; Kreter, B; Nichols, RL; Rodgers, A; Wilson, SE; Zervos, M | 1 |
16 review(s) available for vancomycin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Humans; Linezolid; Methicillin; Methicillin-Resistant Staphylococcus aureus; Penicillins; Skin Diseases, Bacterial; Staphylococcus aureus; Vancomycin | 2022 |
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Topics: Animals; Anti-Bacterial Agents; Cost Savings; Gram-Positive Bacterial Infections; Hospitalization; Humans; Length of Stay; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2018 |
MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bacteremia; Biomarkers; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Vancomycin | 2018 |
Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis; Retrospective Studies; Skin Diseases, Bacterial; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2019 |
Linezolid versus vancomycin for skin and soft tissue infections.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Drug Eruptions; Humans; Length of Stay; Linezolid; Oxazolidinones; Pruritus; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Thrombocytopenia; Vancomycin | 2013 |
Does vancomycin have a future in the treatment of skin infections?
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
What's new in the treatment of serious MRSA infection?
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Drug Administration Routes; Drug Therapy, Combination; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2014 |
Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
Topics: Anti-Bacterial Agents; Drug-Related Side Effects and Adverse Reactions; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin | 2015 |
Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.
Topics: Acute Disease; Anti-Bacterial Agents; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Skin Diseases, Bacterial; Vancomycin | 2015 |
Linezolid versus vancomycin for skin and soft tissue infections.
Topics: Adult; Anti-Bacterial Agents; Drug Eruptions; Humans; Length of Stay; Linezolid; Pruritus; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Thrombocytopenia; Vancomycin | 2016 |
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
Topics: Anti-Bacterial Agents; Bayes Theorem; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Oxazolidinones; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2017 |
Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Topics: Acetamides; Anti-Bacterial Agents; Bacteremia; Drug-Related Side Effects and Adverse Reactions; Gram-Positive Bacterial Infections; Humans; Linezolid; Oxazolidinones; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin | 2010 |
The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Cross Infection; Humans; Linezolid; Methicillin Resistance; Oxazolidinones; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2010 |
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
Topics: Anti-Bacterial Agents; Communicable Diseases; Drug Resistance, Bacterial; Enterococcus; Humans; Methicillin-Resistant Staphylococcus aureus; Minocycline; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2011 |
Update on linezolid: the first oxazolidinone antibiotic.
Topics: Acetamides; Administration, Oral; Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Positive Cocci; Humans; Injections, Intravenous; Linezolid; Oxazolidinones; Pneumonia, Bacterial; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Teicoplanin; Vancomycin | 2005 |
Dalbavancin: a review for dermatologists.
Topics: Acetamides; Adult; Animals; Catheterization; Clinical Trials, Phase III as Topic; Cross Infection; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Enterococcus; Female; Fever; Gram-Positive Bacterial Infections; Headache; Humans; Linezolid; Male; Methicillin Resistance; Microbial Sensitivity Tests; Oxazolidinones; Rabbits; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Teicoplanin; Treatment Outcome; Vancomycin | 2006 |
40 trial(s) available for vancomycin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2021 |
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aztreonam; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Humans; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2017 |
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pyrimidines; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2018 |
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Aztreonam; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2018 |
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Aged; Female; Gram-Positive Bacteria; Humans; Male; Middle Aged; Pyrimidines; Skin Diseases, Bacterial; Vancomycin | 2018 |
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin | 2018 |
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Double-Blind Method; Humans; Pyrimidines; Skin Diseases, Bacterial; Substance Abuse, Intravenous; Treatment Outcome; Vancomycin | 2019 |
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Diterpenes; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pleuromutilins; Polycyclic Compounds; Skin; Skin Diseases, Bacterial; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2013 |
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Topics: Acetamides; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Linezolid; Male; Middle Aged; Oxazolidinones; Skin Diseases, Bacterial; Teicoplanin; Vancomycin; Young Adult | 2014 |
Single-dose oritavancin in the treatment of acute bacterial skin infections.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Drug Administration Schedule; Female; Glycopeptides; Humans; Infusions, Intravenous; Intention to Treat Analysis; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Nausea; Skin Diseases, Bacterial; Vancomycin; Young Adult | 2014 |
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Female; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin; Young Adult | 2015 |
A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Female; Fluoroquinolones; Humans; Linezolid; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2016 |
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vancomycin; Young Adult | 2016 |
Daptomycin for Complicated Skin Infections: A Randomized Trial.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Clindamycin; Creatine Kinase; Daptomycin; Diarrhea; Drug Administration Schedule; Female; Fever; Gram-Positive Bacterial Infections; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Single-Blind Method; Skin Diseases, Bacterial; Vancomycin | 2017 |
Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Topics: Acetamides; Adolescent; Adult; Aged; Anti-Bacterial Agents; China; Cross Infection; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin | 2008 |
Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
Topics: Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; International Agencies; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Skin Diseases, Bacterial; Tigecycline; Treatment Outcome; Vancomycin | 2008 |
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Cross Infection; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Skin Diseases, Bacterial; Vancomycin | 2009 |
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2010 |
In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Skin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Vancomycin | 2010 |
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Treatment Outcome; Vancomycin | 2010 |
The impact of linezolid and vancomycin treatment on local signs and symptoms of inflammation among pediatric patients with complicated skin and skin structure infections.
Topics: Acetamides; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Gram-Positive Bacterial Infections; Hospitalization; Humans; Infant; Linezolid; Male; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Pediatrics; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2011 |
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Nausea; Skin Diseases, Bacterial; Taiwan; Tigecycline; Vancomycin; Vomiting | 2011 |
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2012 |
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Glycopeptides; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin; Skin Diseases, Bacterial; Staphylococcal Infections; Vancomycin | 2012 |
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Topics: Acetamides; Administration, Oral; Aged; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Length of Stay; Linezolid; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Probability; Prognosis; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcus aureus; Treatment Outcome; Vancomycin; Wound Infection | 2003 |
Linezolid for the treatment of complicated skin and skin structure infections in children.
Topics: Acetamides; Administration, Oral; Age Factors; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Female; Gram-Positive Bacterial Infections; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Linezolid; Male; Oxazolidinones; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2003 |
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Middle Aged; Penicillins; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2005 |
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Topics: Acetamides; Adult; Aged; Anti-Infective Agents; Female; Humans; Internationality; Linezolid; Male; Methicillin Resistance; Middle Aged; Oxazolidinones; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2005 |
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacteria; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Random Allocation; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2005 |
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Topics: Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Positive Cocci; Humans; India; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Nausea; North America; Skin Diseases, Bacterial; South America; Streptococcus pyogenes; Tigecycline; Treatment Outcome; Vancomycin; Vomiting | 2005 |
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aztreonam; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Minocycline; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2005 |
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Penicillins; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2006 |
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Topics: Aged; Ceftazidime; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin | 1996 |
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Gr
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Hospitalization; Humans; Male; Middle Aged; Oxacillin; Penicillins; Skin Diseases, Bacterial; Vancomycin; Virginiamycin | 1999 |
39 other study(ies) available for vancomycin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.
Topics: Animals; Anti-Bacterial Agents; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterococcus faecalis; Gram-Positive Bacterial Infections; Methicillin; Mice; Microbial Sensitivity Tests; Molecular Structure; Skin Diseases, Bacterial; Staphylococcus aureus; Structure-Activity Relationship; Vancomycin; Wound Infection | 2018 |
Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department.
Topics: Anti-Bacterial Agents; Emergency Service, Hospital; Glycopeptides; Humans; Lipoglycopeptides; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2022 |
Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Middle Aged; Retrospective Studies; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2019 |
Characterization of Pathogens Isolated from Cutaneous Abscesses in Patients Evaluated by the Dermatology Service at an Emergency Department.
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clindamycin; Dermatology; Emergency Service, Hospital; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Puerto Rico; Schools, Medical; Skin Diseases, Bacterial; Staphylococcus aureus; Tetracycline; Vancomycin; Young Adult | 2020 |
A multi-center clinical investigation on invasive Streptococcus pyogenes infection in China, 2010-2017.
Topics: Ceftriaxone; Child, Preschool; China; Clindamycin; Drug Resistance, Bacterial; Erythromycin; Female; Fever; Humans; Infant; Infant, Newborn; Male; Penicillins; Pneumonia, Pneumococcal; Retrospective Studies; Sepsis; Shock, Septic; Skin Diseases, Bacterial; Soft Tissue Infections; Streptococcal Infections; Streptococcus pyogenes; Tertiary Care Centers; Vancomycin | 2019 |
Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Cefazolin; Female; Hospitalization; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Skin Diseases, Bacterial; Skin Diseases, Infectious; Sulbactam; Treatment Outcome; Vancomycin | 2013 |
Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Costs and Cost Analysis; Drug Therapy, Combination; Economics, Hospital; Formularies, Hospital as Topic; Humans; Length of Stay; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2013 |
Comparative analysis of empiric antimicrobial treatments for skin and soft tissue infections in newly hospitalized patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Electronic Health Records; Female; Hospitalization; Humans; Length of Stay; Likelihood Functions; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Survival Analysis; Treatment Outcome; Vancomycin | 2014 |
Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000-2009.
Topics: Anti-Bacterial Agents; Birth Weight; Clindamycin; Enterocolitis, Necrotizing; Hospital Mortality; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Length of Stay; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Retrospective Studies; Sepsis; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus; Tennessee; Vancomycin | 2014 |
Pharmacology and the treatment of complicated skin and skin-structure infections.
Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Lipoglycopeptides; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections.
Topics: Acetamides; Acute Disease; Administration, Intravenous; Anti-Bacterial Agents; Daptomycin; Health Expenditures; Humans; Linezolid; Oxazolidinones; Patient Discharge; Skin Diseases, Bacterial; Soft Tissue Infections; United States; Vancomycin | 2014 |
Dalbavancin or oritavancin for skin infections.
Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Dalbavancin or oritavancin for skin infections.
Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Dalbavancin or oritavancin for skin infections.
Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Dalbavancin or oritavancin for skin infections.
Topics: Anti-Bacterial Agents; Female; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Dalbavancin or oritavancin for skin infections.
Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
Topics: Anti-Bacterial Agents; Female; Humans; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin | 2014 |
Cochrane in context: Linezolid versus vancomycin for skin and soft tissue infections.
Topics: Acetamides; Anti-Bacterial Agents; Humans; Oxazolidinones; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
[Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
Topics: Aztreonam; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
Reply to DiNubile.
Topics: Anti-Bacterial Agents; Bacteremia; Cefazolin; Female; Glycopeptides; Humans; Male; Methicillin Resistance; Skin Diseases, Bacterial; Staphylococcal Infections; Vancomycin | 2015 |
Trials and tribulations of noninferiority: caveat emptor.
Topics: Anti-Bacterial Agents; Bacteremia; Cefazolin; Female; Glycopeptides; Humans; Male; Methicillin Resistance; Skin Diseases, Bacterial; Staphylococcal Infections; Vancomycin | 2015 |
Vancomycin Use in Patients Discharged From the Emergency Department: A Retrospective Observational Cohort Study.
Topics: Abscess; Administration, Intravenous; Adult; Anti-Bacterial Agents; Emergency Service, Hospital; Female; Humans; Inappropriate Prescribing; Male; Medical Audit; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Patient Discharge; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Vancomycin | 2015 |
Editorial Commentary: Double Gram-Positive Coverage for Acute Bacterial Skin and Skin Structure Infections: Has the Eagle Landed?
Topics: Anti-Bacterial Agents; Clindamycin; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2015 |
Vancomycin Combined With Clindamycin for the Treatment of Acute Bacterial Skin and Skin-Structure Infections.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Diarrhea; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Patient Readmission; Retrospective Studies; Skin Diseases, Bacterial; Vancomycin | 2015 |
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Topics: Anti-Bacterial Agents; Daptomycin; Drug Resistance, Multiple, Bacterial; Enterococcus; Europe; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; North America; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus; Streptococcal Infections; Streptococcus; Vancomycin | 2015 |
Can We Better Optimize Vancomycin Monotherapy?
Topics: Anti-Bacterial Agents; Clindamycin; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2016 |
Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
Topics: Acute Disease; Ambulatory Care; Anti-Bacterial Agents; Comorbidity; Cost Savings; Decision Trees; Emergency Service, Hospital; Glycopeptides; Hospitalization; Humans; Lipoglycopeptides; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2016 |
Staphylococcus lugdunensis infections, filling in the gaps: a 3-year retrospective review from a comprehensive cancer center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus lugdunensis; Vancomycin; Young Adult | 2017 |
Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
Topics: Anti-Bacterial Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Drug Administration Schedule; Humans; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Streptococcus; Teicoplanin; Vancomycin | 2008 |
When less is more: high-dose, short duration regimens and antibiotic resistance.
Topics: Anti-Bacterial Agents; Daptomycin; Drug Resistance, Microbial; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Penicillins; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Vancomycin | 2008 |
Outcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infections.
Topics: Anti-Bacterial Agents; Cohort Studies; Databases as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Care Costs; Hospitalization; Humans; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retreatment; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Time Factors; Treatment Outcome; Vancomycin | 2009 |
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Drug Resistance, Bacterial; Enterococcus; Exotoxins; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Leukocidins; Lipoglycopeptides; Microbial Sensitivity Tests; Population Surveillance; Skin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus; Staphylococcus aureus; Streptococcus; Vancomycin | 2010 |
Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
Topics: Acetamides; Acinetobacter baumannii; Carbapenems; Drug Evaluation; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Humans; Klebsiella pneumoniae; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Oxazolidinones; Skin; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2012 |
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
Topics: Anti-Bacterial Agents; Diterpenes; Drugs, Investigational; Enterococcus; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Skin; Skin Diseases, Bacterial; Staphylococcus; Streptococcus; Vancomycin | 2012 |
Early endpoints for acute bacterial skin and skin structure infections.
Topics: Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2012 |
Cutaneous Bacillus cereus infection in an immunocompetent patient.
Topics: Adult; Anti-Bacterial Agents; Bacillus cereus; Female; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Vancomycin | 2002 |
[Bacterial colonization of chronic wounds. Studies on outpatients in a university dermatology clinic with special consideration of ORSA].
Topics: Aged; Aged, 80 and over; Bacteriological Techniques; Chronic Disease; Clindamycin; Drug Resistance, Multiple, Bacterial; Erythromycin; Female; Foot Ulcer; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Oxacillin; Penicillin Resistance; Pressure Ulcer; Radiodermatitis; Skin Diseases, Bacterial; Skin Ulcer; Staphylococcal Skin Infections; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin; Vancomycin Resistance; Varicose Ulcer; Wound Infection | 2004 |
Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
Topics: Acetamides; Humans; Linezolid; Methicillin Resistance; Oxazolidinones; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Streptococci isolated from various skin lesions: the interaction with Staphylococcus aureus strains.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Erythromycin; Fluoroquinolones; Fusidic Acid; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillins; Skin Diseases, Bacterial; Species Specificity; Streptococcal Infections; Streptococcus; Vancomycin | 1999 |